Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 06, 2025 – CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI(R) net revenue was $11.2 million, a 12% increase […]